| 摘要 |
A process is disclosed for the manufacture of a pharmaceutically acceptable salt of escitalopram (formula (II), Z is -CN, R<1>R<2>=Me) characterised in that escitalopram free base is precipitated in solid form from a solvent and separated from the solvent, optionally re-crystallised one or more times, and then transformed into a salt of escitalopram. Preferably, the salt is escitalopram oxalate and the free base is precipitated from a crude escitalopram which has previously been subjected to initial purification. By this process, the impurity of formula (II) (Z is -CN, R<1>=Me, R<2>=H) is rduced in amount or removed. |
